Corneal Toxicity in Patients Receiving Antibody–Drug Conjugates for the Treatment of Cancer

Download this slideset based on the content from a live satellite symposium with an overview of how treatment with antibody–drug conjugates can cause ocular toxicity for patients with cancer.

Asim V. Farooq, MD Released: November 12, 2021

Download this slideset based on the content from a live satellite symposium with a case study of the antibody–drug conjugate belantamab mafodotin and the potential for ocular toxicity while receiving this treatment for myeloma.

Paul G. Richardson, MD Released: November 12, 2021

Download this slideset based on the content from a live satellite symposium on how to best manage ocular toxicity resulting from therapy with antibody–drug conjugates for patients with cancer.

Joann Kang, MD Released: November 12, 2021

Gain key clinical insights fast, with this short slideset from CCO on key considerations for recognizing and managing ocular toxicities associated with antibody–drug conjugates.

Asim V. Farooq, MD Joann Kang, MD Paul G. Richardson, MD Released: November 29, 2021